ATE254469T1 - Verfahren zur verminderung der renalen aufnahme von antikörperfragmenten - Google Patents

Verfahren zur verminderung der renalen aufnahme von antikörperfragmenten

Info

Publication number
ATE254469T1
ATE254469T1 AT96910422T AT96910422T ATE254469T1 AT E254469 T1 ATE254469 T1 AT E254469T1 AT 96910422 T AT96910422 T AT 96910422T AT 96910422 T AT96910422 T AT 96910422T AT E254469 T1 ATE254469 T1 AT E254469T1
Authority
AT
Austria
Prior art keywords
antibody fragments
reducing renal
lysine
renal uptake
poly
Prior art date
Application number
AT96910422T
Other languages
English (en)
Inventor
Thomas M Behr
David M Goldenberg
Original Assignee
Ct Molecular Med & Immunology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Molecular Med & Immunology filed Critical Ct Molecular Med & Immunology
Application granted granted Critical
Publication of ATE254469T1 publication Critical patent/ATE254469T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6895—Rescue therapy; Agonist-antagonist; Antidotes; Targeted rescue or protection, e.g. by folic acid-folinic acid or conjugated to antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT96910422T 1995-03-21 1996-03-20 Verfahren zur verminderung der renalen aufnahme von antikörperfragmenten ATE254469T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/407,899 US5843894A (en) 1995-03-21 1995-03-21 Methods for reduced renal uptake of antibody fragments
PCT/US1996/003308 WO1996029087A1 (en) 1995-03-21 1996-03-20 Methods for reduced renal uptake of antibody fragments

Publications (1)

Publication Number Publication Date
ATE254469T1 true ATE254469T1 (de) 2003-12-15

Family

ID=23614010

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96910422T ATE254469T1 (de) 1995-03-21 1996-03-20 Verfahren zur verminderung der renalen aufnahme von antikörperfragmenten

Country Status (9)

Country Link
US (4) US5843894A (de)
EP (1) EP0767673B1 (de)
JP (1) JPH10505866A (de)
AT (1) ATE254469T1 (de)
CA (1) CA2190867C (de)
DE (1) DE69630761T2 (de)
ES (1) ES2211951T3 (de)
IL (1) IL117564A (de)
WO (1) WO1996029087A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843894A (en) * 1995-03-21 1998-12-01 Center For Molecular Medicine And Immunology Methods for reduced renal uptake of antibody fragments
AU5727000A (en) * 1999-06-07 2000-12-28 Center For Molecular Medicine And Immunology Alpha or beta emitters attached to fragments in radioimmunotherapy
JP2003504395A (ja) * 1999-07-16 2003-02-04 マリンクロッド・インコーポレイテッド 腎臓に有害な可能性のある分子の腎臓取り込みの阻害
EP1862172A1 (de) * 2006-05-31 2007-12-05 BioSynthema Inc. Zusammensetzung von einer Aminosäurelösung und Gelatine zur Hemmung renaler Aufnahme
WO2013106824A1 (en) * 2012-01-13 2013-07-18 Board Of Regents, The University Of Texas System Epherin receptor targeting agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283342A (en) * 1992-06-09 1994-02-01 Neorx Corporation Biotinylated small molecules
US4701521A (en) * 1978-07-17 1987-10-20 The Trustees Of Boston University Method of effecting cellular uptake of molecules
US5595734A (en) * 1988-04-06 1997-01-21 Alfacell Corporation Compositions comprising ONCONASE (tm) and lovastatin
WO1991004755A1 (en) * 1989-09-29 1991-04-18 Neorx Corporation Methods for reducing non-target retention of immunoconjugates and metabolites thereof
US5225180A (en) * 1991-09-10 1993-07-06 Diatech, Inc. Technetium-99m labeled somatostatin-derived peptides for imaging
US5843894A (en) * 1995-03-21 1998-12-01 Center For Molecular Medicine And Immunology Methods for reduced renal uptake of antibody fragments
US5840296A (en) * 1997-10-15 1998-11-24 Raines; Ronald T. Engineered cytotoxic ribonuclease A

Also Published As

Publication number Publication date
DE69630761T2 (de) 2004-09-23
US20030203836A1 (en) 2003-10-30
AU700346B2 (en) 1999-01-07
EP0767673A1 (de) 1997-04-16
CA2190867C (en) 2009-06-02
IL117564A0 (en) 1996-07-23
US20020111300A1 (en) 2002-08-15
US20060182683A1 (en) 2006-08-17
ES2211951T3 (es) 2004-07-16
EP0767673B1 (de) 2003-11-19
DE69630761D1 (de) 2003-12-24
WO1996029087A1 (en) 1996-09-26
US5843894A (en) 1998-12-01
EP0767673A4 (de) 1999-08-04
IL117564A (en) 2005-03-20
CA2190867A1 (en) 1996-09-26
JPH10505866A (ja) 1998-06-09
AU5361696A (en) 1996-10-08

Similar Documents

Publication Publication Date Title
DE59904569D1 (de) Therapeutikum zur unterdrückung von schnarchgeräuschen
DK0807125T3 (da) Monoklonale antistoffer mod CD6 til behandling og diagnosticering af psoriasis
BR0206985A (pt) Anticorpos modificados e métodos de uso
NO985464L (no) Konsentrert antistoffpreparat
HUT76970A (hu) Készítmény az érrendszer specifikus koagulálásához
UA41297C2 (uk) Похідні індолу, фармацевтична композиція і спосіб лікування
ATE368054T1 (de) Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität
HUP9802556A1 (hu) Eljárás és készítmény kötőszöveti kapcsolódások gyógyítására és helyreállítására
EP0679093A1 (de) Methode zum überbringen von agenzien an zielzellen.
FR10C0015I2 (fr) Molecules d'anticorps a specificite pour le facteur alpha de necrose tumorale humaine, et leurs utilisations
PT1017675E (pt) Derivados da camtotecina altamente lipofilos
BR0107749A (pt) Métodos de uso de uma composição de bebida
DK1098643T3 (da) Phenylacetylglutamin, phenylacetylisoglutamin og/eller phenylacetat til behandling af neoplastiske sygdomme
DK0998287T3 (da) Anvendelse af levobupivacain
NO971341D0 (no) Promoter for reseptor tyrosinkinase TIE
DE69725860D1 (de) PLAN ZUR VERABREICHUNG VON H+, K+-ATPase INHIBITOREN
CY1107623T1 (el) Μεθοδος αγωγης συμπτωματων ορμονικων μεταβολων, περιλαμβανομενων των εξαψεων
BR9811861A (pt) Polipeptìdeos de fatores de crescimento ligantes de heparina (fclh)
HUP0202776A2 (hu) (+)-Tramadol, O-demetil-tramadol, (+)-O-demetil-tramadol, O-demetil-N-mono-demetil-tramadol, illetve (+)-O-demetil-N-mono-demetil-tramadol felhasználása vizeletinkontinencia kezelésére alkalmas gyógyszerkészítmény előállítására
TR199900770T2 (xx) Nazal poliplerin tedavisinde bir H+, K+-ATPase'�n kullan�lmas�.
DE69631542D1 (de) Neue geranylgeranylderivate, verfahren zu deren herstellung und entsprechende pharmazeutische zusammensetzungen
DE69630761D1 (de) Verfahren zur verminderung der renalen aufnahme von antikörperfragmenten
PT1007040E (pt) Utilizacao de fanquinona no tratamento da doenca de alzheimer
DE69921486D1 (de) Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
SE9902597D0 (sv) New use

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties